Detection of RAS mutations in circulating tumor cells: applications in colorectal cancer and prospects

Denis, Jérôme Alexandre

doi:10.1684/abc.2017.1304

Cited by 6 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Morphologic identification uses cytological analysis or markers' identification through immunohistochemistry or immunofluorescence. Molecular biology techniques like in situ hybridization (FISH) perform the ARN analysis and, in association with RT-PCR, can identify specific mutations (33). Immunohistochemistry using monoclonal antibodies in CTC identification has low sensitivity and requires prior tumor cells' enrichment (34).…”

Section: Discussionmentioning

confidence: 99%

Assessment of circulating tumor cells in peripheral blood using flow cytometry in patients with surgery for colorectal cancer – review

Muşină

Huțanu

Zlei

et al. 2020

Revista Romana De Medicina De Laborator

View full text Add to dashboard Cite

Introduction: Colorectal cancer (CRC) is the third most common neoplasia in the world. Circulating tumor cells (CTC) have a prognostic value and can be useful in monitoring solid neoplasia. Only one method for CTC identification has received the approval and this is the CellSearch® system based on the immunomagnetic separation. Multiple markers are used in CTC identification, as epithelial markers and cytokeratines. CTC identification in peripheral blood is associated with a worse prognostic and reduced free survival in CRC.Material and methods: We performed a systematic search in PubMed database for articles that reports the circulating tumor cells in CRC until July 2019. We selected studies in English and French and the main words used for search were ‘circulating tumor cells’, ‘colorectal cancer’, ‘colon cancer’, ‘rectal cancer’, ‘flow cytometry’, ‘peripheral blood’. We included studies with more than 10 patients, where samples were collected from the blood in relation with surgery and flow cytometry was used as analyzing technique.Results: We included 7 studies in final analysis, that showed in flow cytometry analysis a cut-off value of CTC that can vary from 2-4 CTC/ 7.5 ml peripheral blood with a sensitivity of 50.8% and specificity of 95%. Patients with positive CTC were associated with higher T stage and positive lymph nodes, with a worse overall survival (OS) and disease free survival (DFS) comparing with negative patients.Conclusion: CTC are considered to be a prognostic factor who needs more validation studies in order to be included in the clinical practice.

show abstract

Section: Discussionmentioning

confidence: 99%

Assessment of circulating tumor cells in peripheral blood using flow cytometry in patients with surgery for colorectal cancer – review

Muşină

Huțanu

Zlei

et al. 2020

Revista Romana De Medicina De Laborator

View full text Add to dashboard Cite

show abstract

“… 56 Nanoparticles are being used to capture cancer biomarkers including cancer-associated proteins, 57 , 58 circulating tumor DNA (ctDNA), 59 , 60 circulating tumor cells (CTC), and exosomes. 61 , 62 Antibodies, small molecules, peptides, aptamers, and other compounds can be thickly coated on nanoparticle surfaces because of this high surface area-to-volume ratio. Multivalent effects can be obtained by presenting multiple binding ligands to cancer cells, which can improve the specificity and sensitivity of diagnosis.…”

Section: Application Of Nanotechnology For Cancer Diagnosis and Treat...mentioning

confidence: 99%

Nanotechnology: A Promising Approach for Cancer Diagnosis, Therapeutics and Theragnosis

Dessale¹,

Mengistu²,

Mengist³

2022

IJN

View full text Add to dashboard Cite

Cancer remains the most devastating disease and the major cause of mortality worldwide. Although early diagnosis and treatment are the key approach in fighting against cancer, the available conventional diagnostic and therapeutic methods are not efficient. Besides, ineffective cancer cell selectivity and toxicity of traditional chemotherapy remain the most significant challenge. These limitations entail the need for the development of both safe and effective cancer diagnosis and treatment options. Due to its robust application, nanotechnology could be a promising method for in-vivo imaging and detection of cancer cells and cancer biomarkers. Nanotechnology could provide a quick, safe, cost-effective, and efficient method for cancer management. It also provides simultaneous diagnosis and treatment of cancer using nano-theragnostic particles that facilitate early detection and selective destruction of cancer cells. Updated and recent discussions are important for selecting the best cancer diagnosis, treatment, and management options, and new insights on designing effective protocols are utmost important. This review discusses the application of nanotechnology in cancer diagnosis, therapeutics, and theragnosis and provides future perspectives in the field.

show abstract

“…they are termed as "oncogenes" [1,2]. These genes are mutated and/or overexpressed at high levels in tumor cells.…”

mentioning

confidence: 99%

“…Normally, cells repair themselves or undergo apoptosis if there is an interruption on the cell cycle. However, the high expression of multiple oncogenes, along with mutated apoptotic and/or tumor suppressor genes and exposure to environmental chemicals that trigger such mutations can all act in concert and finally cause tumorigenesis [1][2][3]. In the past 50 years, several oncogenes have been identified in different types of human cancers.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Introductory Chapter: Interactions between Environmental Chemicals and KRAS Oncogene in Different Cancers - Special Focus on Colorectal, Pancreatic, and Lung Cancers

Erkekoğlu¹

2019

Oncogenes and Carcinogenesis

View full text Add to dashboard Cite

Introduction v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) is an oncogene. The KRAS gene is located on the twelfth chromosome and belongs to the Ras family of oncogenes. These proteins play important roles in cell division, cell differentiation, and apoptotic cell death. Induction of KRAS with different environmental chemicals leads to high expression of K-Ras protein, which in turn causes high cellular proliferation. These cascade of events finally initiate certain types of cancers, particularly colorectal (CRC), pancreatic, and lung cancers. High calorie intake, diets rich in meat and fat, smoking, and alcohol consumption are the major risk factors of CRCs, and it was estimated that in CRC, mutated KRAS has an incidence of ∼50%. Exposure to certain environmental chemicals [organochlorine insecticides such as DDT and its metabolite dichlorodiphenyltrichloroethylene (DDE); herbicides such as EPTC and pendimethalin; N-nitrosamines; polychlorinated biphenyls (PCBs); benzene] and drugs (anti-diabetics drugs) can also contribute to the increased incidence of PC throughout the world. It was stated that in adenocarcinomas of the pancreas, mutated KRAS has an incidence of ∼70-90%. Lung cancer is the leading cause of deaths worldwide. KRAS gene mutations are much more common in long-term tobacco smokers with lung cancer when compared to nonsmokers. KRAS gene mutations are observed in 15-25% of all lung cancer cases, being more frequent in whites vs. Asian populations. Lung cancers with KRAS gene mutations typically indicate a poor prognosis and are associated with resistance to several cancer treatments. This chapter mainly focuses on KRAS, interactions between environmental chemicals, and KRAS oncogene in different cancers, particularly in colorectal, pancreatic, and lung cancers. Most oncogenes are expressed as proto-oncogenes, involved in cell growth and proliferation or inhibition of apoptosis. If there are chemical, physical, or biological factors that cause mutations in such genes promoting cellular growth, these genes are mostly upregulated and cellular proliferation increases [1]. The cascade of events leading to proliferation usually predisposes the cell to cancer. In this case,

show abstract

Detection of RAS mutations in circulating tumor cells: applications in colorectal cancer and prospects

Cited by 6 publications

References 0 publications

Assessment of circulating tumor cells in peripheral blood using flow cytometry in patients with surgery for colorectal cancer – review

Assessment of circulating tumor cells in peripheral blood using flow cytometry in patients with surgery for colorectal cancer – review

Nanotechnology: A Promising Approach for Cancer Diagnosis, Therapeutics and Theragnosis

Introductory Chapter: Interactions between Environmental Chemicals and KRAS Oncogene in Different Cancers - Special Focus on Colorectal, Pancreatic, and Lung Cancers

Contact Info

Product

Resources

About